{"nct_id":"NCT00560794","title":"Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","status_verified_date":"2014-12","start_date":"2008-01","start_date_type":null,"primary_completion_date":"2009-09","primary_completion_date_type":"ACTUAL","completion_date":"2014-11","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["AMGN"]}